REGION VI RCE - NONHUMAN PRIMATE CORE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 NIAID呼吁建立强大的基础设施和多方面的研究与开发活动，将最好的基础、转化和临床科学应用于产生新的诊断、治疗和疫苗对策，以应对构成生物恐怖主义威胁的A、B和C类病原体，德克萨斯州、新墨西哥州、俄克拉荷马州、阿肯色州和路易斯安那州的22个机构联合了他们的力量，创造力和资源，以创建西部（VI区）生物防御和新兴传染病卓越中心（WRCE）。九个科学核心将提供最先进的蛋白质组学，基因组学，标准化的小动物和非人灵长类动物传染病模型，BSL-4实验室设施和GLP放大生产，以及计算生物学中的横切功能和简化的疫苗和药物转化开发流程，以获得FDA批准。传统竞争机构之间一贯强烈的合作精神建立了一个项目，核心和管理的联锁网络，将加强和蓬勃发展的中心实施。这个互动研究项目和核心资源设施网络的指导将在一个全面的行政计划下执行，通过履行一个共同主题的精心制定的科学战略，为国家的生物防御使命做出重大贡献;合作开发基于宿主病原体生物学的新型疫苗，诊断和治疗生物威胁剂。 有一个明确的共识，即非人灵长类动物将是NIAID A类和B类药物的治疗和疫苗开发的必要组成部分。对于其中许多药物，人体试验将非常有限或不可能。此外，还需要适当的动物BL 3设施和人员在BL 3和可能的BL 4条件下处理灵长类动物，以确保有效和及时地将治疗和疫苗的进展转移给人类。 RCE的NHP核心将：1。监督和协助研究者在本提案中使用非人灵长类动物获取动物，并确保遵守联邦动物福利和生物安全法规; 2.为分配到本计划项目的非人灵长类动物提供常规兽医护理和饲养; 3.提供专业知识和援助，在设计和实施实验使用非人灵长类动物; 4.为使用非人类灵长类动物的研究提供临床和病理学实验室支持; 5.开发新的和创新的非人类灵长类动物资源，用于测试治疗和疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In response to NIAID's call for the creation of strong infrastructure and multifaceted research and development activities applying the best basic, translational, and clinical science to the generation of new diagnostic, therapeutic and vaccine countermeasures for Category A, B, and C pathogens posing threats as agents of bioterrorism, 22 institutions in Texas, New Mexico, Oklahoma, Arkansas, and Louisiana have combined their energy, creativity, and resources to create the Western (Region Vl) Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE). Nine scientific cores will provide access to state-of-the-art proteomics, genomics, standardized small animal and non-human primate models of infectious diseases, BSL-4 laboratory facilities, and GLP scale-up production, as well as crosscutting functions in computational biology and a streamlined process for translational development of vaccines and drugs leading to FDA approval. A consistently strong spirit of cooperation among traditionally competing institutions has established an interlocking network of projects, cores, and administration that will strengthen and flourish as the Center is implemented. The guidance of this network of interactive research projects and core resource facilities will be executed under a comprehensive administrative plan to contribute substantially to the nation's biodefense mission by fulfilling a carefully crafted scientific strategy on a common theme; Collaborations for host-pathogen biology based development of novel vaccines, diagnostics, and therapeutics against biothreat agents. There is a clear consensus that nonhuman primates will be a necessary part of the development of therapeutics and vaccines for the NIAID Class A and Class B agents. For many of these agents, human trials will be very limited or impossible. In addition, appropriate animal BL3 facilities and personnel trained in the handling of primates under BL3 and perhaps BL4 conditions will be necessary in order to ensure efficient and timely transfer of advances in therapeutics and vaccines to the human population. The NHP Core of the RCE will: 1. provide oversight and assistance in the acquisition of animals by investigators using nonhuman primates in this proposal and assure compliance with federal animal welfare and biosafety regulations; 2. provide for the routine veterinary care and husbandry for nonhuman primates assigned to projects contained within this program; 3. provide expertise and assistance in the design and implementation of experiments using nonhuman primates; 4. provide for clinical and pathology laboratory support for studies using nonhuman primates; 5. develop new and innovative nonhuman primate resources for use in testing therapeutics and vaccines.